Addressing Asthma and Respiratory Health

Why asthma and respiratory health matters
Nationally, asthma, bronchiolitis and other respiratory illnesses are a leading cause of children’s hospitalizations and missed school and work days with an estimated cost of $56 billion annually. The Centers for Disease Control and Prevention estimate that 9.3% of children in the United States under the age of 18 had a diagnosis of asthma in 2012.....

Read more here: childrenscolorado.org

------------------------------------------------------

Hikma teams up with Vectura to develop generic asthma drug

Vectura has extended its relationship with Hikma after the two UK-listed pharmaceutical companies signed another agreement to work together to develop a generic inhaled drug.
Vectura, a FTSE-250 company that specialises in formulating powders and inhalation devices for people with asthma and chronic obstructive pulmonary disease, will partner with generic drug specialist Hikma to develop and commercialise salmeterol, a generic version of GlaxoSmithKline's respiratory drug Serevent.....

Read more here: telegraph.co.uk

------------------------------------------------------

Fighting for the next Asthma Blockbuster: Italy gets in the way of Novartis

Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster. Can it take on Novartis in the competition for what is expected to grow to a €24B market in 2024?
Chiesi is an Italian pharma with a strong focus on respiratory diseases. To strengthen its pipeline, the company has acquired the British Atopix Therapeutics for an amount that could exceed €75M if all milestones are met. With this deal, Chiesi incorporates OC459, a CRTh2 antagonist, to its pipeline.....

Read more here: labiotech.eu